These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

43 related articles for article (PubMed ID: 28820684)

  • 21. Limited Ability of Posaconazole To Cure both Acute and Chronic Trypanosoma cruzi Infections Revealed by Highly Sensitive In Vivo Imaging.
    Francisco AF; Lewis MD; Jayawardhana S; Taylor MC; Chatelain E; Kelly JM
    Antimicrob Agents Chemother; 2015 Aug; 59(8):4653-61. PubMed ID: 26014936
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antiprotozoal drug nitazoxanide enhances parasitemia, tissue lesions and mortality caused by Trypanosoma cruzi in murine model.
    Valle-Reyes JS; Melnikov V; Dobrovinskaya O; Rodriguez-Hernández A; Wookee-Zea C; Pimientel-Rodrigez V; Rueda-Valdovinos G; Delgado-Enciso I; López-Lemus UA; Espinoza-Gómez F
    Exp Parasitol; 2017 Jan; 172():44-50. PubMed ID: 28011170
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Benznidazole and Posaconazole in Eliminating Parasites in Asymptomatic T. Cruzi Carriers: The STOP-CHAGAS Trial.
    Morillo CA; Waskin H; Sosa-Estani S; Del Carmen Bangher M; Cuneo C; Milesi R; Mallagray M; Apt W; Beloscar J; Gascon J; Molina I; Echeverria LE; Colombo H; Perez-Molina JA; Wyss F; Meeks B; Bonilla LR; Gao P; Wei B; McCarthy M; Yusuf S;
    J Am Coll Cardiol; 2017 Feb; 69(8):939-947. PubMed ID: 28231946
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The use of posaconazole against Chagas disease.
    Molina I; Salvador F; Sánchez-Montalvá A
    Curr Opin Infect Dis; 2015 Oct; 28(5):397-407. PubMed ID: 26203852
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chagas disease in Latin America: an epidemiological update based on 2010 estimates.
    Wkly Epidemiol Rec; 2015 Feb; 90(6):33-43. PubMed ID: 25671846
    [No Abstract]   [Full Text] [Related]  

  • 26. Recent clinical trials for the etiological treatment of chronic chagas disease: advances, challenges and perspectives.
    Urbina JA
    J Eukaryot Microbiol; 2015; 62(1):149-56. PubMed ID: 25284065
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Randomized trial of posaconazole and benznidazole for chronic Chagas' disease.
    Molina I; Gómez i Prat J; Salvador F; Treviño B; Sulleiro E; Serre N; Pou D; Roure S; Cabezos J; Valerio L; Blanco-Grau A; Sánchez-Montalvá A; Vidal X; Pahissa A
    N Engl J Med; 2014 May; 370(20):1899-908. PubMed ID: 24827034
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chagas disease. What is known and what should be improved: a systemic review.
    Coura JR; Borges-Pereira J
    Rev Soc Bras Med Trop; 2012 Jun; 45(3):286-96. PubMed ID: 22760123
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Trypanosoma cruzi and Chagas' Disease in the United States.
    Bern C; Kjos S; Yabsley MJ; Montgomery SP
    Clin Microbiol Rev; 2011 Oct; 24(4):655-81. PubMed ID: 21976603
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Epidemiology of American trypanosomiasis (Chagas disease).
    Kirchhoff LV
    Adv Parasitol; 2011; 75():1-18. PubMed ID: 21820549
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Parasitic loads in tissues of mice infected with Trypanosoma cruzi and treated with AmBisome.
    Cencig S; Coltel N; Truyens C; Carlier Y
    PLoS Negl Trop Dis; 2011 Jun; 5(6):e1216. PubMed ID: 21738811
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Advances in Chagas disease drug development: 2009-2010.
    Buckner FS; Navabi N
    Curr Opin Infect Dis; 2010 Dec; 23(6):609-16. PubMed ID: 20885320
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chagas disease: changes in knowledge and management.
    Lescure FX; Le Loup G; Freilij H; Develoux M; Paris L; Brutus L; Pialoux G
    Lancet Infect Dis; 2010 Aug; 10(8):556-70. PubMed ID: 20670903
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chagas disease: a new worldwide challenge.
    Coura JR; Viñas PA
    Nature; 2010 Jun; 465(7301):S6-7. PubMed ID: 20571554
    [No Abstract]   [Full Text] [Related]  

  • 35. Seroprevalence of Trypanosoma cruzi among eleven potential reservoir species from six states across the southern United States.
    Brown EL; Roellig DM; Gompper ME; Monello RJ; Wenning KM; Gabriel MW; Yabsley MJ
    Vector Borne Zoonotic Dis; 2010 Oct; 10(8):757-63. PubMed ID: 20020815
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Specific chemotherapy of Chagas disease: relevance, current limitations and new approaches.
    Urbina JA
    Acta Trop; 2010; 115(1-2):55-68. PubMed ID: 19900395
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chagas: one hundred years later.
    Jurberg C
    Bull World Health Organ; 2009 Jul; 87(7):491-2. PubMed ID: 19649360
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An estimate of the burden of Chagas disease in the United States.
    Bern C; Montgomery SP
    Clin Infect Dis; 2009 Sep; 49(5):e52-4. PubMed ID: 19640226
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [THERAPEUTIC ACTION OF AMPHOTERICIN B IN ACUTE CHAGAS' DISEASE].
    ABITBOL H; BORIS E; PIULATS E; PODESTA D; MARANON J
    Bol Chil Parasitol; 1964; 19():132-4. PubMed ID: 14224905
    [No Abstract]   [Full Text] [Related]  

  • 40. Anti-Trypanosoma cruzi immunoglobulin G1 can be a useful tool for diagnosis and prognosis of human Chagas' disease.
    Cordeiro FD; Martins-Filho OA; Da Costa Rocha MO; Adad SJ; Corrêa-Oliveira R; Romanha AJ
    Clin Diagn Lab Immunol; 2001 Jan; 8(1):112-8. PubMed ID: 11139203
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.